Sex differences in drug effects: Interaction with sex hormones in adult life

Handbook of Experimental Pharmacology

Volumn 214, Issue , 2012, Pages 91-105

  Spoletini, Ilaria ^a   Vitale, Cristiana ^a   Malorni, Walter ^b   Rosano, Giuseppe M C ^a,c  

^a IRCCS SAN RAFFAELE PISANA   (Italy)

^b ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^c Centre for Clinical Research San Raffaele Sulmona   (Italy)

Author keywords

Drug adverse effects; Estrogen; Pharmacodynamics; Pharmacokinetics; Progesterone; Sex; Testosterone

Indexed keywords

ACETYLSALICYLIC ACID; ANTIARRHYTHMIC AGENT; ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; ANTIHISTAMINIC AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CYTOCHROME P450; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ESTRADIOL; ESTROGEN; FIBRINOGEN RECEPTOR ANTAGONIST; FIBRINOLYTIC AGENT; GASTROINTESTINAL AGENT; GESTAGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LABETALOL; NEUROLEPTIC AGENT; PROGESTERONE; PROPRANOLOL; SEX HORMONE; TESTOSTERONE; DRUG;

ADVERSE DRUG REACTION; ARTICLE; BLEEDING; CONTRACEPTION; COUGHING; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFECT; DRUG ELIMINATION; DRUG EXCRETION; DRUG GLUCURONIDATION; DRUG METABOLISM; DRUG PROTEIN BINDING; ELECTROLYTE DISTURBANCE; ESTROGEN DEFICIENCY; HORMONE SUBSTITUTION; HUMAN; MENOPAUSE; MENSTRUAL CYCLE; MYOPATHY; PHARMACODYNAMICS; PLASMA PROTEIN BINDING; PREGNANCY; PRIORITY JOURNAL; QT PROLONGATION; SEX DIFFERENCE; TACHYCARDIA; TORSADE DES POINTES; UNSPECIFIED SIDE EFFECT; ABSORPTION; ADULT; FEMALE; MALE; PHARMACOLOGY; PHYSIOLOGY; REVIEW; SEXUAL DEVELOPMENT; TISSUE DISTRIBUTION;

ABSORPTION; ADULT; FEMALE; GONADAL STEROID HORMONES; HUMANS; MALE; PHARMACEUTICAL PREPARATIONS; PHARMACOLOGY; SEX CHARACTERISTICS; TISSUE DISTRIBUTION;

EID: 84868334415     PISSN: 01712004     EISSN: 18650325     Source Type: Book Series    
DOI: 10.1007/978-3-642-30726-3_5     Document Type: Article

References (44)

1. Institute of medicine exploring the biological contributions to human health: does sex matter? http://www.nap.edu/catalog/10028.html
2. Anthony M (2005) Male/female differences in pharmacology: safety issues with QT-prolonging drugs. J Womens Health (Larchmt) 14:47-52
3. Arias-Loza PA, Hu K, Dienesch C et al (2007) Both estrogen receptor subtypes, alpha and beta, attenuate cardiovascular remodeling in aldosterone salt-treated rats. Hypertension 50:432-438
4. Boersma E, Harrington RA, Moliterno DJ et al (2002) Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet 359:189-198
5. Custodio JM, Wu CY, Benet LZ (2008) Predicting drug disposition, absorption/elimination/transporter interplay and the role of food on drug absorption. Adv Drug Deliv Rev 60:717-733
6. De Silva TM, Broughton BR, Drummond GR et al (2009) Gender influences cerebral vascular responses to angiotensin II through Nox2-derived reactive oxygen species. Stroke 40:1091-1097
7. Everson GT (1992) Gastrointestinal motility in pregnancy. Gastroenterol Clin North Am 21:751-776
8. Fischer M, Baessler A, Schunkert H (2002) Renin angiotensin system and gender differences in the cardiovascular system. Cardiovasc Res 53:672-677
9. Franconi F, Brunelleschi S, Steardo L et al (2007) Gender differences in drug responses. Pharmacol Res 55:81-95
10. Franconi F, Carru C, Malorni W et al (2011a) The effect of sex/gender on cardiovascular pharmacology. Curr Pharm Des 17:1095-1107
11. Franconi F, Sanna M, Straface E et al (2011b) Pharmacokinetics and pharmacodynamics: the role of sex and gender. In: Oertelt-Prigione S, Regitz-Zagrosek V (eds) Sex and Gender aspects in clinical medicine. Springer, London
12. Gandhi M, Aweeka F, Greenblatt RM et al (2004) Sex differences in pharmacokinetics and pharmacodynamics. Annu Rev Pharmacol Toxicol 44:499-523
13. Gilmore DA, Gal J, Gerber JG et al (1992) Age and gender influence the stereoselective pharmacokinetics of propranolol. J Pharmacol Exp Ther 261:1181-1186
14. Hagg S, Spigset O, Dahlqvist R (2001) Influence of gender and oral contraceptives on CYP2D6 and CYP2C19 activity in healthy volunteers. Br J Clin Pharmacol 51:169-173
15. Hinojosa-Laborde C, Chapa I, Lange D et al (1999) Gender differences in sympathetic nervous system regulation. Clin Exp Pharmacol Physiol 26:122-126
16. Jochmann N, Stangl K, Garbe E et al (2005) Female-specific aspects in the pharmacotherapy of chronic cardiovascular diseases. Eur Heart J 26:1585-1595
17. Johnson JA, Akers WS, Herring VL et al (2000) Gender differences in labetalol kinetics: importance of determining stereoisomer kinetics for racemic drugs. Pharmacotherapy 20:622-628
18. Krecic-Shepard ME, Barnas CR, Slimko J et al (2000) Faster clearance of sustained release verapamil in men versus women: continuing observations on sex-specific differences after oral administration of verapamil. Clin Pharmacol Ther 68:286-292
19. Kurokawa J, Suzuki T, Furukawa T (2009) New aspects for the treatment of cardiac diseases based on the diversity of functional controls on cardiac muscles: acute effects of female hormones on cardiac ion channels and cardiac repolarization. J Pharmacol Sci 109:334-340
20. Leinwand LA (2003) Sex is a potent modifier of the cardiovascular system. J Clin Invest 112:302-307
21. Luzier AB, Killian A, Wilton JH et al (1999) Gender-related effects on metoprolol pharmacokinetics and pharmacodynamics in healthy volunteers. Clin Pharmacol Ther 66:594-601
22. Malorni W, Campesi I, Straface E et al (2007) Redox features of the cell: a gender perspective. Antioxid Redox Signal 9:1779-1801
23. Malorni W, Straface E, Matarrese P et al (2008) Redox state and gender differences in vascular smooth muscle cells. FEBS Lett 582:635-642
24. Oertelt-Prigione S, Regitz-Zagrosek V (2009) Gender aspects in cardiovascular pharmacology. J Cardiovasc Transl Res 2:258-266
25. Ostadal B, Netuka I, Maly J et al (2009) Gender differences in cardiac ischemic injury and protection-experimental aspects. Exp Biol Med (Maywood) 234:1011-1019
26. Patel H, Bell D, Molokhia M et al (2007) Trends in hospital admissions for adverse drug reactions in England: analysis of national hospital episode statistics 1998-2005. BMC Clin Pharmacol 7:9
27. Pirmohamed M, James S, Meakin S et al (2004) Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ 329:15-19
28. Pretorius M, Luther JM, Murphey LJ et al (2005) Angiotensin-converting enzyme inhibition increases basal vascular tissue plasminogen activator release in women but not in men. Arterioscler Thromb Vasc Biol 25:2435-2440
29. Qayyum R, Becker DM, Yanek LR et al (2008) Platelet inhibition by aspirin 81 and 325 mg/day in men versus women without clinically apparent cardiovascular disease. Am J Cardiol 101:1359-1363
30. Rathore SS, Wang Y, Krumholz HM (2002) Sex-based differences in the effect of digoxin for the treatment of heart failure. N Engl J Med 347:1403-1411
31. Regitz-Zagrosek V (2006) Therapeutic implications of the gender-specific aspects of cardiovascular disease. Nat Rev Drug Discov 5:425-438
32. Rosano GM, Leonardo F, Dicandia C et al (2000) Acute electrophysiologic effect of estradiol 17beta in menopausal women. Am J Cardiol 86(1385-7):A5-A6
33. Rosano GM, Leonardo F, Sarrel PM et al (1996) Cyclical variation in paroxysmal supraventricular tachycardia in women. Lancet 347:786-788
34. Schwartz JB (2003a) Gender-specific implications for cardiovascular medication use in the elderly optimizing therapy for older women. Cardiol Rev 11:275-298
35. Schwartz JB (2003b) The influence of sex on pharmacokinetics. Clin Pharmacokinet 42:107-121
36. Schwartz JB (2007) The current state of knowledge on age, sex, and their interactions on clinical pharmacology. Clin Pharmacol Ther 82:87-96
37. Shekelle PG, Rich MW, Morton SC et al (2003) Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: a meta-analysis of major clinical trials. J Am Coll Cardiol 41:1529-1538
38. Singh S, Zoble RG, Yellen L et al (2000) Efficacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation or atrial flutter: the symptomatic atrial fibrillation investigative research on dofetilide (SAFIRE-D) study. Circulation 102:2385-2390
39. Soldin OP, Mattison DR (2009) Sex differences in pharmacokinetics and pharmacodynamics. Clin Pharmacokinet 48:143-157
40. Spranger M, Aspey BS, Harrison MJ (1989) Sex difference in antithrombotic effect of aspirin. Stroke 20:34-37
41. Thurmann PA, Haack S, Werner U et al (2006) Tolerability of beta-blockers metabolized via cytochrome P450 2D6 is sex-dependent. Clin Pharmacol Ther 80:551-553
42. Wiegratz I, Kutschera E, Lee JH et al (2003) Effect of four different oral contraceptives on various sex hormones and serum-binding globulins. Contraception 67:25-32
43. Zhu B, Liu ZQ, Chen GL et al (2003) The distribution and gender difference of CYP3A activity in Chinese subjects. Br J Clin Pharmacol 55:264-269
44. Zingone MM, Guirguis AB, Airee A et al (2009) Probable drug interaction between warfarin and hormonal contraceptives. Ann Pharmacother 43:2096-2102